Elsevier

Peptides

Volume 17, Issue 8, 1996, Pages 1261-1265
Peptides

Article
Could dual G-protein coupling explain [d-Met2]FMRFamide's mixed action in vivo?

https://doi.org/10.1016/S0196-9781(96)00196-9Get rights and content

Abstract

In vitro studies have demonstrated that FMRFamide-related peptide receptors can be coupled to different G-proteins, mediating opposite stimulatory and inhibitory effects. The present study tested whether this duality might extend to effects in vivo. Antinociception in mice of ICV [d-Met2]FMRFamide, which produced agonist [ED50 = 36.3 μg (61.6 nmol)] and antagonist [ID50 = 0.72 μg (1.22 nmol)] actions, was attenuated by 24-h pretreatment with ICV pertussis toxin (ID50 = 0.55 μg) or cholera toxin (ID50 = 0.09 μg), suggesting that [d-Met2]FMRFamide in vivo effects might also be explained by dual GiGs coupling.

References (25)

  • J.E. Zadina et al.

    Interactions of Tyr-MIF-1 at opiate receptor sites

    Pharmacol. Biochem. Behav.

    (1986)
  • X.Z. Zhu et al.

    Low affinity inhibition of opioid receptor binding by FMRFamide

    Neuropeptides

    (1986)
  • Cited by (13)

    • On the G protein-coupling selectivity of the native A<inf>2B</inf> adenosine receptor

      2018, Biochemical Pharmacology
      Citation Excerpt :

      The possibility of a GPCR coupling to multiple G proteins has been proposed previously, including for β2 and β3 adrenergic [45,46]; luteinizing hormone [47], follicle stimulating hormone [48], δ-opioid [49], and cannabinoid CB1 [50] receptors. It has been suggested that FMRFamide-related mixed action in vivo might be related to dual Gi/Gs coupling, based on studies using PTX and CTX [51]. The coupling to multiple G proteins has been the best characterized for the β2 receptor, including the demonstration that both Gi and Gs pathways under the β2 receptor are involved in heart function [52–54].

    View all citing articles on Scopus
    View full text